Holen Sie sich die Stockscreener-App
15.38
4.59%
-0.74
Handel nachbörslich:
15.40
0.02
+0.13%
Acadia Pharmaceuticals Inc Aktie (ACAD) Neueste Nachrichten
DEADLINE TOMORROW: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against ACADIA Pharmaceuticals Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm - Business Wire
ACADIA Pharmaceuticals Earns Relative Strength Rating Upgrade - Investor's Business Daily
Why Is Acadia (ACAD) Down 11.1% Since Last Earnings Report? - Yahoo Finance
Soleno breaks through with FDA nod for Prader-Willi syndrome treatment Vykat XR - Fierce Pharma
Soleno jumps as analysts say US nod for rare disease drug transforms treatment options - Marketscreener.com
SLNO Stock Rallies on FDA Approval of Prader-Willi Syndrome Drug - Yahoo Finance
Acadia Pharmaceuticals principal accounting officer sells $18k in stock By Investing.com - Investing.com Canada
Acadia Pharmaceuticals CFO sells $54,065 in stock By Investing.com - Investing.com Canada
Acadia Pharmaceuticals CFO sells $54,065 in stock - Investing.com India
Acadia Pharmaceuticals principal accounting officer sells $18k in stock - Investing.com
Is ACADIA Pharmaceuticals Inc. (ACAD) a Promising Biotech Stock According to Wall Street Analysts - Insider Monkey
Psychosis in Parkinson's and Alzheimer's Disease Market: - openPR
Parkinson's Disease Psychosis Treatment Market Size in 7MM - openPR
Acadia Pharmaceuticals Initiates Phase 2 Clinical Trial of ACP-204 for the Treatment of Alzheimer’s Disease Psychosis - Business Wire
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Acadia Pharmaceuticals Announces DAYBUE™ (trofinetide) is Now Available for the Treatment of Rett Syndrome - Business Wire
Is ACADIA Pharmaceuticals Inc. (ACAD) the Best Nasdaq Stock Under $20 to Buy Now? - Insider Monkey
ACADIA Pharmaceuticals Earns RS Rating Upgrade - Investor's Business Daily
Former San Diego Pharma VP pleads guilty to securities fraud for insider trading - MSN
Ryan Reynolds Announces More to Parkinson’s® Campaign - Business Wire
Acadia Pharmaceuticals issues new employee stock awards By Investing.com - Investing.com Australia
Acadia Pharmaceuticals issues new employee stock awards - Investing.com India
Acadia Expands Neuroscience Team with Strategic Stock Grants to 13 Key Hires - Stock Titan
Acadia Sets Stage for Strategic Updates at 3 Major CNS ConferencesKey Dates for Investors - StockTitan
ACADIA Pharmaceuticals’ SWOT analysis: stock outlook amid pipeline progress By Investing.com - Investing.com South Africa
ACADIA Pharmaceuticals’ SWOT analysis: stock outlook amid pipeline progress - Investing.com India
Proficio Capital Partners LLC Invests $272,000 in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) - Defense World
Parkinson's Disease Therapeutics Market is expected to reach - openPR
ACADIA Pharmaceuticals Q4 Earnings: EPS Soars to $0.86, Beating Estimates, While Revenue Misses at $259.6 Million - GuruFocus.com
Calif. Pharma Exec Pleads Guilty To Insider Trading - Law360
SEC Sues Former Acadia Pharmaceuticals VP Over Insider Trading - Bloomberg Law News
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Acadia Pharmaceuticals (ACAD) Investors with Losses to Contact Its Attorneys, Firm Investigating ACAD for Possible Securities Law Violations - ACCESS Newswire
Former Vice President of San Diego-Based Acadia Pharmaceutical Company Admits to Insider Trading - Sierra Sun Times
ACADIA Pharmaceuticals (NASDAQ:ACAD) Earns Equal Weight Rating from Morgan Stanley - Defense World
Ex-San Diego pharma VP pleads guilty to securities fraud for insider trading - ABC 10 News San Diego KGTV
Former Acadia Pharmaceuticals VP Pleads Guilty to Insider Trading in San Diego Federal Court - Hoodline
Former Executive Pleads Guilty to Insider Trading in FDA Drug Case - NewsBreak
ACADIA Pharmaceuticals (NASDAQ:ACAD) Upgraded at StockNews.com - Defense World
Ex-San Diego biotech company CEO admits to illegally selling $1.3M worth of shares - FOX 5 San Diego
Former Pharmaceutical Executive Pleads Guilty After $1.3M Gain from Insider Trading - Times of San Diego
Balanced Outlook for ACADIA Pharmaceuticals Amid Uncertain Long-term Growth Prospects - TipRanks
ACADIA Pharmaceuticals, Inc. to Host Earnings Call - ACCESS Newswire
ACADIA Pharmaceuticals Inc. to Host Earnings Call - ACCESS Newswire
Why ACADIA Pharmaceuticals Stock Took a Hit - TipRanks
ACADIA Pharmaceuticals Director Makes Significant Stock Sale - TipRanks
Insider Sell: Elizabeth Garofalo Sells 4,919 Shares of ACADIA Ph - GuruFocus.com
Acadia Pharmaceuticals director Elizabeth Garofalo sells $89,673 in stock By Investing.com - Investing.com South Africa
Acadia Pharmaceuticals director Elizabeth Garofalo sells $89,673 in stock - Investing.com India
3.01%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):